227 related articles for article (PubMed ID: 25538270)
1. Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.
Rodriguez-Barradas MC; Serpa JA; Munjal I; Mendoza D; Rueda AM; Mushtaq M; Pirofski LA
J Infect Dis; 2015 Jun; 211(11):1703-11. PubMed ID: 25538270
[TBL] [Abstract][Full Text] [Related]
2. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.
Simell B; Nurkka A; Ekström N; Givon-Lavi N; Käyhty H; Dagan R
Clin Vaccine Immunol; 2012 Oct; 19(10):1618-23. PubMed ID: 22875604
[TBL] [Abstract][Full Text] [Related]
3. Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines.
Madhi SA; Izu A; Violari A; Cotton MF; Jean-Philippe P; Otwombe K; Adrian PV;
Vaccine; 2020 Mar; 38(12):2651-2659. PubMed ID: 32070681
[TBL] [Abstract][Full Text] [Related]
4. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
[TBL] [Abstract][Full Text] [Related]
8. Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.
Ohtola JA; Saul-McBeth JL; Iyer AS; Leggat DJ; Khuder SA; Khaskhely NM; Westerink MJ
J AIDS Clin Res; 2016 Mar; 7(3):. PubMed ID: 27158552
[TBL] [Abstract][Full Text] [Related]
9. Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
Ulanova M; Huska B; Dubois S; McCready W
Vaccine; 2022 Jul; 40(32):4594-4602. PubMed ID: 35738971
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
11. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
12. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.
Feikin DR; Elie CM; Goetz MB; Lennox JL; Carlone GM; Romero-Steiner S; Holder PF; O'Brien WA; Whitney CG; Butler JC; Breiman RF
Clin Diagn Lab Immunol; 2004 Jan; 11(1):137-41. PubMed ID: 14715560
[TBL] [Abstract][Full Text] [Related]
13. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
Ahmed F; Steinhoff MC; Rodriguez-Barradas MC; Hamilton RG; Musher DM; Nelson KE
J Infect Dis; 1996 Jan; 173(1):83-90. PubMed ID: 8537687
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
[TBL] [Abstract][Full Text] [Related]
15. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.
Feikin DR; Elie CM; Goetz MB; Lennox JL; Carlone GM; Romero-Steiner S; Holder PF; O'Brien WA; Whitney CG; Butler JC; Breiman RF
Vaccine; 2001 Nov; 20(3-4):545-53. PubMed ID: 11672921
[TBL] [Abstract][Full Text] [Related]
18. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
[TBL] [Abstract][Full Text] [Related]
19. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.
Bamford A; Kelleher P; Lyall H; Haston M; Zancolli M; Goldblatt D; Kampmann B
AIDS; 2014 Sep; 28(14):2033-43. PubMed ID: 25222526
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]